Amgen ( AMGN) rated new Buy at Stifel Nicolaus. $68 price target. Company has the only major new product among its peers.

Celanese ( CE) upgraded at Citigroup from Hold to Buy. $35 price target. Company is growing in China, which should also help keep costs down.

Celgene ( CELG) rated new Buy at Stifel Nicolaus. $71 price target. Company has superior growth prospects.

Gilead Sciences ( GILD) rated new Hold at Stifel Nicolaus. Valuation call, as the company is facing patent expirations.

Idexx Laboratories ( IDXX) rated new Market Perform at Leerink. Stock is already pricing in the company's organic growth potential.

Skilled Healthcare Group ( SKH) upgraded at Credit Suisse to Neutral from Underperform as the company agreed to a $50 million settlement in the Lavender case. The settlement was significantly lower than the Street's expectation, Credit Suisse said. Price target increased to $5 from $2.

Teva Pharmaceutical ( TEVA) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $65 price target. Effexor XR launch was strong and the company should post better earnings in the second half of 2010.

Tellabs ( TLAB) downgraded at Soleil from Buy to Hold. $8 price target. Estimates also cut, as the company is losing market share at Soleil.

Valspar ( VAL) was downgraded at Citigroup from Buy to Hold. $32 price target. Paint sales tailed off toward the end of summer, as the housing market soured.


Altera ( ALTR) estimates, target increased through 2011 at Citigroup. Company boosted guidance at its midquarter update. Buy rating and new $36 price target.

Arris ( ARRS) estimates, target lowered at UBS. Estimates cut through 2011. Cable CapEx spending could be slowing down, along with the broader economy. Neutral rating and new $9 price target.

Allegheny Energy ( AYE) numbers boosted at Citigroup. Shares of AYE now seen reaching $24, according to Citigroup. Estimates also upped, as the company is cutting costs and should see higher regulated earnings. Hold rating.

Coca-Cola Enterprises ( CCE) numbers raised at UBS. Shares of CCE now seen reaching $34, according to UBS. Estimates also increased, to match the company's new guidance. Buy rating.

Chesapeake Midstream Partners ( CHKM) estimates cut at Barclays. 2011 EPS estimate lowered to $1.51, 2010 held at $1.05. Chesapeake Midstream reported second-quarter results in line, Barclays said. Maintain Overweight rating and $26 target.

Hasbro ( HAS) target upped to $52 at Keybanc. Company held an upbeat investor meeting, and the Hub channel remains on track for launch. Buy rating.

Las Vegas Sands ( LVS) numbers raised at JP Morgan. Shares of LVS now seen reaching $36, according to JP Morgan. Estimates also increased, given better results in Singapore. Overweight rating.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback